Clinical Trials Logo

Toxemia clinical trials

View clinical trials related to Toxemia.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT01273779 Suspended - Severe Sepsis Clinical Trials

Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis

OASIS
Start date: June 2011
Phase: Phase 2/Phase 3
Study type: Interventional

Study will evaluate the safety and potential benefit of talactoferrin (recombinant human lactoferrin) as an addition to the standard care for severe sepsis.

NCT ID: NCT00563134 Suspended - Sepsis Clinical Trials

A Randomised Trial on the Saftely and Efficacy of GR270774 in the Treatment of Gram-negative Sepsis in Adult

Start date: October 2005
Phase: N/A
Study type: Interventional

Sepsis sometimes occurs in people who have a serious infection. It is caused by toxic substances (toxins) from bacteria and other germs entering your bloodstream. Most people with sepsis will recover with routine medical care before the illness gets more serious. However, in some people, sepsis does become more serious. This severe sepsis can cause damage to internal organs (such as your heart, lungs, kidneys, and liver) and can be life threatening. Special natural fats, (called 'lipoproteins') in our blood are thought to help protect us from the toxins produced by bacteria during sepsis. Levels of these lipoproteins are often low in people with sepsis and this may make it more difficult to recover from the disease. GR270773 is a new drug that has been developed to help the lipoproteins in protecting the body against toxins. GR270773 is made from purified fats and oils from the soyabean and does not contain cholesterol. This research study will test the safety (side effects) of GR270773 and whether or not it is effective in preventing complications in people with severe sepsis.